Alaunos Therapeutics, Inc. Logo

Alaunos Therapeutics, Inc.

Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.

TCRT | US

Overview

Corporate Details

ISIN(s):
US98973P1012
LEI:
Country:
United States of America
Address:
501 E LAS OLAS BLVD, 33301 FORT LAUDERDALE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alaunos Therapeutics, Inc. is a clinical-stage cellular immuno-oncology company focused on developing T-cell receptor (TCR-T) cell therapies for the treatment of solid tumors. The company engineers therapies to target neoantigens that arise from specific genomic 'hotspot' mutations in cancer cells. Its approach utilizes the proprietary hunTR® platform, a discovery engine for expanding its TCR library, and the 'Sleeping Beauty' non-viral transposition technology. This manufacturing process is designed to be rapid, flexible, and cost-effective, aiming to deliver tumor-specific T cells to cancer patients with significant unmet clinical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Alaunos Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alaunos Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alaunos Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MAINZ BIOMED N.V. Logo
Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.
United States of America MYNZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.